RERF-GC-1BHomo sapiens (Human)Cancer cell line

Also known as: Radiation Effects Research Foundation-Gastric Cancer-1B, RerfGC1B, RERFGC1B

🤖 AI SummaryBased on 8 publications

Quick Overview

Human gastric cancer cell line with ZAK isoform upregulation and potential for drug sensitivity studies.

Detailed Summary

RERF-GC-1B is a human gastric cancer cell line derived from a primary tumor, characterized by the preferential upregulation of the ZAK kinase isoform TV1. This cell line exhibits significant alterations in gene expression and copy number, making it a valuable model for studying gastric cancer biology and therapeutic responses. The overexpression of ZAK TV1 has been linked to activation of multiple cancer-related signaling pathways, suggesting its potential as a therapeutic target. Additionally, RERF-GC-1B shows sensitivity to targeted therapies, making it a useful tool for preclinical drug development and personalized medicine research.

Research Applications

Gastric cancer biologyZAK kinase isoform studiesDrug sensitivity profilingTargeted therapy development

Key Characteristics

Preferential upregulation of ZAK TV1Altered gene expression and copy numberSensitivity to targeted therapies
Generated on 6/19/2025

Basic Information

Database IDCVCL_3152
SpeciesHomo sapiens (Human)
Tissue SourcePyloric lymph node[UBERON:UBERON_0015866]

Donor Information

Age41
Age CategoryAdult
SexMale
Raceasian

Disease Information

DiseaseGastric adenocarcinoma
LineageEsophagus/Stomach
SubtypeStomach Adenocarcinoma
OncoTree CodeSTAD

DepMap Information

Source TypeHSRRB
Source IDACH-000144_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg213Ter (c.637C>T)Unspecified-Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12,13
D13S317
12
D16S539
11
D18S51
13
D21S11
29,30
D3S1358
15,16
D5S818
10,12
D7S820
10,13
D8S1179
15,17
FGA
22
Penta D
8,11
Penta E
12,24
TH01
9
TPOX
11
vWA
14,18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer.

Firestein R., Zhang Z.-M.

Nat. Commun. 5:3830.1-3830.8(2014).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization.

Okanoue T., Inazawa J.

Cancer Sci. 96:100-110(2005).